Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
暂无分享,去创建一个
E. Swisher | I. McNeish | S. Goble | R. Shapira-Frommer | R. Kristeleit | G. Freyer | B. You | O. Colomban | L. Maloney | K. Lin
[1] B. Monk,et al. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Pavlidis,et al. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside , 2022, Cancers.
[3] E. Swisher,et al. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Antonios Revythis,et al. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer , 2022, International journal of environmental research and public health.
[5] Aruni Ghose,et al. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era , 2022, Proteomes.
[6] M. Devouassoux‐Shisheboran,et al. The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review , 2021, Cancers.
[7] S. Lheureux,et al. The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. , 2021, Cancer treatment reviews.
[8] A. Tinker,et al. 751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group , 2021, Annals of Oncology.
[9] O. Trédan,et al. 733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study , 2021, Annals of Oncology.
[10] I. McNeish,et al. Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial. , 2021 .
[11] Natalie Y L Ngoi,et al. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? , 2021, ESMO open.
[12] A. Tinker,et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) , 2021, Nature Communications.
[13] J. Ledermann,et al. The Systemic Treatment of Recurrent Ovarian Cancer revisited. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] R. Kristeleit,et al. Rucaparib versus chemotherapy in patients with advanced , relapsed ovarian cancer and a deleterious BRCA mutation : Efficacy and safety from ARIEL 4 , a randomized phase III study Presenting , 2021 .
[15] S. Shah,et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] B. Lin,et al. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. , 2020, Life sciences.
[17] M. van der Aa,et al. 847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands , 2020 .
[18] E. Kohn,et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Gulati,et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.
[20] I. Ray-Coquard,et al. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial , 2020, Clinical Cancer Research.
[21] D. Timmerman,et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] I. Ray-Coquard,et al. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study , 2019, Clinical Cancer Research.
[23] F. Saad,et al. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Cesar M. Castro,et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. , 2017, Gynecologic oncology.
[25] H. Chung,et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. , 2017, Gynecologic oncology.
[26] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[27] Ayala Hubert,et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.
[28] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Oza,et al. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). , 2013, Gynecologic oncology.
[30] B Richter,et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer , 2011, British Journal of Cancer.
[31] V. Gebski,et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. , 2011, Journal of the National Cancer Institute.
[32] M. Parmar,et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.
[33] E Comets,et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. , 2007, British journal of clinical pharmacology.
[34] E. Eisenhauer,et al. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .
[35] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[36] H E Lambert,et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.